主页 > 医学前沿 >
【drug-news】一箭双雕：抗艾滋病药物Gilead获准治
Mon Aug 11, 2008 7:17pm EDT
LOS ANGELES (Reuters) - Gilead Sciences said on Monday it won U.S. approval to promote its AIDS drug Viread for treating adults with chronic hepatitis B.
Hepatitis B is a potentially life-threatening infection that can destroy the liver. Gilead estimates that more than 400 million people worldwide have the disease, which is most prevalent in Asian countries. It is the leading cause of liver cancer and complications kill up to 1.2 million people per year.
Viread, known generically as tenofovir, is a once-daily tablet that works by blocking an enzyme necessary for the virus to replicate in liver cells.
The drug has been available in the United States as a treatment for HIV infection in adults since 2001.
Gilead already markets another hepatitis B drug, Hepsera, which saw second-quarter sales of $90 million.
RBC Capital Markets analyst Jason Kantor estimated that Hepsera currently has 44 percent of the market, which remains significantly underserved.
"Compared to the available drugs, Viread is likely to be considered best-in-class based on its potency, resistance profile, long-term safety, and price," he said in a recent research note.
Truvada, which had second-quarter sales of $516 million, is a pill that combines Viread with Emtriva, another of Gilead's HIV drugs.
Shares of Gilead, which lost 34 cents to close at $56.43 on Nasdaq, were slightly higher at $57.23 in after hours trading. Year-to-date, the stock is up about 24 percent, compared with a gain of about 11 percent for the Biotech Index.
(Reporting by Deena Beasley in Los Angeles and Lisa Richwine in Washington; editing by Carol Bishopric)
http://www.reuters.com/article/healthNews/idUSN1140630020080811 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Gilead wins OK to promote drug for hepatitis B
吉尔德制造抗乙肝药物获得成功
Mon Aug 11, 2008 7:17pm EDT
周一 8月11 2008，7：17 美国东部时间
LOS ANGELES (Reuters) - Gilead Sciences said on Monday it won U.S. approval to promote its AIDS drug Viread for treating adults with chronic hepatitis B.
洛杉矶（路透社） 吉尔德的科学家周一称他们已经获得批准，将生产本来用于治疗艾滋病的药物Viread（替诺福韦）用来治疗成人的慢性乙肝。
Hepatitis B is a potentially life-threatening infection that can destroy the liver. Gilead estimates that more than 400 million people worldwide have the disease, which is most prevalent in Asian countries. It is the leading cause of liver cancer and complications kill up to 1.2 million people per year.
乙肝是一种潜在威胁生命的感染性疾病，它能对肝脏造成损害。吉尔德估计全世界大约4亿多人患有乙肝，在亚洲地区尤为盛行。每年由于乙肝导致的肝癌和并发症夺走了120万人的生命。
Viread, known generically as tenofovir, is a once-daily tablet that works by blocking an enzyme necessary for the virus to replicate in liver cells.
Viread，通用名为替诺福韦 水平有限，希望大家指教！ 吉尔德制造抗乙肝药物获得成功
美国东部时间 2008,8月11 ,7：17 星期一
洛杉矶（路透社） 吉尔德的科学家周一称他们已经获得批准，将生产本来用于治疗艾滋病的药物Viread（替诺福韦）用来治疗成人的慢性乙肝。
乙肝是一种潜在威胁生命的感染性疾病，它能对肝脏造成损害。吉尔德估计全世界大约4亿多人患有乙肝，在亚洲地区尤为盛行。每年由于乙肝导致的肝癌和并发症夺走了120万人的生命。
Viread，通用名为替诺福韦，每天服用一片就可以来治疗乙肝，而它是通过阻止病毒在肝细胞内复制所需要的酶来起作用。
从2001年起，美国已经可以用替诺福韦来治疗感染艾滋病的成人患者。
吉尔德已经上市的抗乙肝药物阿德福韦酯，二季度已达到九千万美元的销售额。
RBC资产分析员杰森.坎特估计阿德福韦酯目前已有44%的市场份额，市场尚未饱和。
他在最近的一篇研究报告中称，与其他药物相比，替诺福韦可以凭借其抗病毒谱、长期的安全性和销售价格，极有可能成为同类药物的佼佼者。
诺福韦，一种曲他丁和替诺福韦的组合物药丸，在第二季度已取得了5.16亿美元的销售额，
在纳斯达克股市，吉尔德的股票头天跌了34美分收于56.43美元，一小时交易后便微涨至57.23美元。年初至今，相比生物技术指数的11%利润，吉尔德的股票却增长了34%。
（洛杉矶的蒂娜.比斯利和华盛顿的利萨.瑞切文采写了报道，由卡罗.博瑞克编辑。） Viread, known generically as tenofovir——Viread，通用名为替诺福韦
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-26 05:11
医学,生命科学网